Suven bags 4 patents in Australia, Eurasia, Israel, US
The Dollar Business Bureau Suven Life Sciences has received patents for its New Chemical Entities (NCEs) in Australia, Eurasia, Israel and USA. The new drug is used in the treatment of cognitive impairment related with neurodegenerative disorders. The patents are valid till 2032, 2030 and 2031 respectively, the company said in a statement on Monday. With these, Suven has around twenty-four granted patents from Australia, seventeen patents from Eurasia, nine from Israel and another twenty-four from USA. These granted patents are intellectual property of the company. They are accomplished through the firm’s internal efforts of the research and development team, it said. The granted patents include the class of selective H3 ligands from Suven which are being developed as therapeutic agents for neurodegenerative ...
Indian firm secures drug patents in five countries
The Dollar Business Bureau Hyderabad-based biopharmaceutical manufacturer Suven Life Sciences Ltd. on Thursday announced that it has secured five product patents in China, Israel, Mexico, Singapore and Sri Lanka. The patents will be used to treat disorders associated with Neurodegenerative diseases. “We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,” said Venkat Jasti, CEO of Suven Life Sciences Ltd. Among the granted patents is the class of selective 5-HT compounds, which was discovered by Suven earlier this year. The patents are being developed as therapeutic agents and will be used to treat neurodegenerative ...
